Turoctocog alfa
Classification: BATC code: B02BD02
Summary
As the substance is almost exclusively used by men, analyses on sex or gender differences have not been considered relevant.
Additional information
Tuructocog alfa is a factor VIII concentrate product used in treatment of acute bleeding episodes, perioperative management and routine prophylaxis patients with hemophilia A [1]. Hemophilia A (deficiency in coagulation factor VIII) is an inherited X-linked disease and thus affects primarily men although women carrying the mutation may have some excess bleeding. The occurrence of hemophilia A in women is very rare and data in women is not available [2].
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of tuructocog alfa have been found.
Effects
No studies with a clinically relevant sex analysis regarding effects of tuructocog alfa have been found.
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of tuructocog alfa have been found.
Reproductive health issues
No studies with a clinically relevant analysis regarding fertility or reproduction of tuructocog alfa have been found. Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Updated: 2020-09-01
Date of litterature search: 2020-05-20
References
- Vakil NH, Fujinami N, Martin-Stone S. Turoctocog alfa for the treatment of hemophilia a. Pharmacotherapy. 2014;34(10):1091-101. PubMed
- NovoEight (turoctocog alfa). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-03-12, cited 2020-05-20].
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk
Reviewed by: Carl-Olav Stiller, Diana Rydberg
Approved by: Karin Schenck-Gustafsson